Overview

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

Status:
Completed

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions

Phase:

Phase 3

Details

Lead Sponsor:

Perrigo Company

Treatments:

Calcium
Calcium, Dietary
Mupirocin